#pharmavoice

We are accustomed to defining the Point of Care (POC) segment of healthcare as physician offices, hospitals, and pharmacies. Also, retail clinics are growing at 25% to 30% annually, adding to the locations where healthcare is available. But, as with everything digitally connected these days, the definition is increasingly out-of-date. As mHealth platforms continue to grow in usability, diversity, and penetration, POC has come to include home computers, mobile phones, tablet computers, and personal digital assistants.

Additionally, the menu of communications and the ways in which POC affects patient care have continued to grow. In this new two-way paradigm, patients are not only receiving information but also delivering it, via wearables that track the details of their conditions and general health, and even by checking their own research and personal experience against what the doctor might recommend.

All this has helped propel the POC sector to a CAGR (compound annual growth rate) of 10% and a current size of $440 million, heading for $500 million or more in 2016. But it brings with it obligations that are rapidly changing how we use the POC opportunities.

Five "Pure Gold" Reasons

Here are 5 key reasons you should attend our complimentary webinar on Dec 12, 2012.

1.     Improve your pharma brand strategy

2.     Learn how to identify the key influencers

3.     Uncover the ways they influence the market

4.     Understand their effects on adherence and market share

5.     See how you can influence the influencers

The Power of Influence:

Connecting Healthcare Influencers to Pharma Brand Strategy

Wednesday – December 12, 2012 / 1:00 pm – 2:00 pm EDT – No cost to attend Please take 3 minutes to register now to secure your spot. Or, learn more about the event before you register.

Can’t attend? Register now to receive access to the OnDemand archive shortly after the event.

Dan Limbach

In cooperation with the Great American Smokeout on November 18, 2010, Core-Create has launched a campaign for the American Cancer Society.

The campaign will be highly visible on commuter trains, billboards, phone kiosks, smartphones, and a microsite. Click on the following link for more information: http://bit.ly/corequitsmoking



Dan Limbach

Are you an iPhone fanatic? Maybe you favor the Blackberry, or the newcomer, the Android platform.

Here's a snarky illustration about how these user groups see themselves and how they are seen by each other.

click on image for full size version

Dan Limbach

There are so many ways to participate in online communities, and the choices can be daunting. Email, Forums, Facebook, Twitter.

In the early days of the commercial Internet (after it was only used as a research tool), I remember having just a few choices. Compuserve, Prodigy, and eventually AOL. There were also Bulletin Board Systems (BBS) you could dial into with your 33K modem. Each were considered online communities in their own right. My, how things have changed. Now there are hundreds of online community platforms, and many come and go like the tides.  Check out this informative "Map" of online communities from XKCD.com. The larger the land mass, the more robust and active the community (it's not solely based on user counts). See how your favorites stack up. You can also use the map to find new areas to explore with your marketing efforts. There could be entire "countries" out there you didn't know existed.

click image for larger view

Dan Limbach

Those of us who were around when computer screens were black with green text (and only text) have seen screen technology come a long way. Now we have 24" flat screen LCD screens with resolutions we could only dream of back then. Look what ideas are possibly in store for us in the next wave.

I recently contributed to an article published in the current May issue of PharmaVoice Magazine entitled “New Course for Biotherapeutics”. The article features various subject matter experts who cover details around the future of biotherapeutics from collaborations to the funding environment. “Companies developing biotherapeutics are beginning to study indications beyond cancer and autoimmune and infectious diseases and are researching how antibodies and proteins can be used to treat other conditions, such as pain and cardiovascular conditions, that have traditionally been treated with small molecules…” 

To read the full article, see PharmaVoice pages 18-20